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Background Meta-analyses of postpartum blood loss and the
effect of uterotonics are biased by visually estimated blood loss.
Objectives To conduct a systematic review of measured
postpartum blood loss with and without prophylactic uterotonics
for prevention of postpartum haemorrhage (PPH).
Search strategy We searched Medline and PubMed terms (labour
stage, third) AND (ergonovine, ergonovine tartrate,
methylergonovine, oxytocin, oxytocics or misoprostol) AND
(postpartum haemorrhage or haemorrhage) and Cochrane reviews
without any language restriction.
Selection criteria Refereed publications in the period 1988–2007
reporting mean postpartum blood loss, PPH (‡500 ml) or severe
PPH (‡1000 ml) following vaginal births.
Data collection and analysis Raw data were abstracted into Excel
by one author and then reviewed by a co-author. Data were
transferred to SPSS 17.0, and copied into RevMan 5.0 to perform
random effects meta-analysis.
Main results The distribution of average blood loss (29 studies) is
similar with any prophylactic uterotonic, and is lower than
without prophylaxis. Compared with no uterotonic, oxytocin and
misoprostol have lower PPH (OR 0.43, 95% CI 0.23–0.81;
OR 0.73, 95% CI 0.50–1.08, respectively) and severe PPH rates
(OR 0.61, 95% CI 0.29–1.29; OR 0.74, 95% CI 0.52–1.04,
respectively). Oxytocin has lower PPH (OR 0.65, 95% CI
0.60–0.70) and severe PPH (OR 0.71, 95% CI 0.56–0.91) rates
than misoprostol, but not in developing countries.
Conclusion Oxytocin is superior to misoprostol in hospitals.
Misoprostol substantially lowers PPH and severe PPH. A sound
assessment of the relative merits of the two drugs is needed in
rural areas of developing countries, where most PPH deaths
occur.
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third stage of labour.
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Introduction
Haemorrhage is the single leading cause of maternal mor-
tality.
1 Postpartum haemorrhage (PPH) is most often
attributed to uterine atony.
2 Most births and maternal
deaths occur in Africa and Asia, where home deliveries are
common, infrastructure and transportation are limited, and
where birth attendants are scarce or inadequately prepared
to prevent and treat PPH.
3 In such settings haemorrhage
accounts for ‡30% of maternal deaths.
1 The United
Nation’s Millennium Development goal 5, to reduce 75%
of maternal mortality by 2015, cannot be reached without
the successful management of PPH.
4,5
The conventional deﬁnition of PPH is a blood loss of
‡500 ml in the ﬁrst 24 hours after delivery.
6,7 By stimulat-
ing uterine muscle tone, prophylactic uterotonics reduce
the incidence of PPH.
2,8,9 Several factors inﬂuence PPH
rates, including whether blood loss is measured, how the
third stage of labour is managed (e.g. the provision of
uterotonic, uterine massage and controlled cord traction),
obstetric interventions carried out (e.g. episiotomy and
mode of delivery), and study population (sample size, par-
ity, urban/rural or facility/home delivery, and level of facil-
ity).
10 Most clinicians (and studies) classify obstetric blood
loss by visual estimation. Visually (clinically) assessed
bleeding underestimates measured blood loss by an average
of 100–150 ml, and substantially underestimates blood loss
of ‡500 ml (by 30–50%).
11–16
Underestimating blood loss ‘lowers’ PPH rates and the
estimates of prevented PPH, as there is artiﬁcially less PPH
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of PPH was 10.55% in 19 studies that measured postpar-
tum blood loss, compared with 7.23% in 22 studies where
blood loss was estimated visually, suggesting a large under-
estimation of PPH.
10 Thus, in meta-analyses such as the
Cochrane reviews of the efﬁcacy of prophylactic uterotonics
to reduce postpartum blood loss and prevent its sequellae,
the proportion of studies and subjects where blood loss
was visually rather than objectively measured inﬂuences the
PPH and severe PPH rates, and thus inﬂuences the esti-
mates (relative risks or odds ratios) of the effectiveness of
uterotonic agents in preventing or treating obstetric haem-
orrhage.
2,8,17–19
Most women experiencing a loss of ‡500 ml of blood
(PPH) do not receive clinical intervention or experience seri-
ous consequences.
10,20,21 In fact, some suggest that the 500-
ml deﬁnition of PPH should be considered an alert level, and
that PPH may be better deﬁned as the volume of blood loss
requiring intervention to avert serious sequellae.
22,23 Accord-
ingly, a re-evaluation of PPH guidelines has been recom-
mended.
24–26 This article presents information about average
blood loss, and the incidence of PPH (‡500 ml) and severe
PPH (‡1000 ml) in studies where blood loss was measured,
to clarify what we know about postpartum blood loss among
women who received and did not receive uterotonic prophy-
laxis during the third stage of labour.
Methods
Searching
Nearly 250 observational and experimental studies pub-
lished up to 31 December 2007 were identiﬁed by Medline
and PubMed online search engines using the following
search terms: (labour stage, third) AND (ergonovine, ergo-
novine tartrate, methylergonovine, oxytocin, oxytocics or
misoprostol) AND (postpartum haemorrhage or haemor-
rhage), without language restriction (Figure 1). Articles
were also identiﬁed and reviewed if cited by the Cochrane
reviews on management of the third stage of labour.
2,8,17,18
Inclusion and exclusion criteria
Studies were retained if there was objective measurement
of blood loss after delivery, regardless of the duration of
the blood measurement, augmentation or induction in the
ﬁrst or second stages of labour, or if other components of
active management of the third stage of labour (AMTSL)
were implemented (Figure 1). Articles published before
1 January 1988, with uncertain blood measurement, includ-
ing one retrospective article,
27 or articles published in jour-
nals that could not be accessed were excluded. Studies
including caesarean deliveries were excluded to avoid
biased comparisons should blood loss vary by delivery
mode.
10 However, studies with twin deliveries were
included as twin and higher order births are relatively rare
events. This review includes all eligible studies regardless of
sample size. Twenty-three of the 59 study arms (39%) had
sample arms of £200.
Assessment of methodological quality
Each study was classiﬁed as a randomised controlled trial
(RCT), quasi-experiment (QE) or observational (Obs).
Study group allocation concealment was classiﬁed as: ade-
quate (i) if a method such as consecutively numbered
sealed opaque envelopes was used; unclear (ii) if the con-
cealment technique was not described; or inadequate (iii) if
there was an open list of random numbers or no random
assignment (e.g. QE) was used.
Data abstraction
All relevant raw data were abstracted from each eligible
study by a single reviewer, and then reviewed by a co-
author. Disagreements were resolved through veriﬁcation
against the publication and discussion. Data were then
transferred to SPSS 17.0 and copied from the data extrac-
tion form into Review Manager (RevMan) 5.0 data anal-
ysis tables (The Cochrane Collaboration, 2008; The Nordic
Cochrane Centre, Copenhagen, Denmark).
Study characteristics
Twenty-nine articles were eligible for the review.
24–26,28–53
Table 1 presents their characteristics (location, sample size,
blood measurement technique and components of AMTSL
implemented). Studies were conducted in low-, middle-
and high-income settings in Africa (n = 6), the Middle East
(n = 4), Asia (n = 4) and Europe (n = 5), with one multi-
country study conducted in all of these regions and Latin
America. All but ﬁve of the studies were conducted in ter-
tiary hospitals. The remaining ﬁve studies included home
births in rural Gambia,
53 home or village subcentre births
in India,
24 home and district hospital births in Vietnam,
32
rural primary health centre births in Guinea-Bissau,
42 and
rural health centre births in India.
52 Most studies measured
blood loss by placing a bedpan underneath the parturient
woman immediately after delivery, usually after the cord
was clamped and cut. The collected blood was generally
poured into a jar for volume measurement, and all soaked
gauze pads were counted and weighed. Relatively few
(n = 6) studies used the fairly new blood collection sheet
or delivery drape, sometimes tied around the woman’s
waist, with a funnel portion hanging between her legs,
including the BRASSS-V Drape  (a calibrated plastic sheet,
Excellent Fixable Drapes, Madurai, Tamil Nadu, India).
54
Two studies used the bedpan and linens method for some
women and the drape for others. Most studies measured
blood loss until active bleeding stopped, regardless of a
pre-speciﬁed duration for blood measurement.
A systematic review of measured postpartum blood loss
ª 2010 Gynuity Health Projects Journal compilation ª RCOG 2010 BJOG An International Journal of Obstetrics and Gynaecology 789Analysis
The range of average postpartum blood loss, rates of PPH
and severe PPH, and ratio of severe PPH to PPH is pre-
sented for all eligible studies. In controlled studies com-
paring different prophylactic regimens, the effects of the
regimen used to manage the third stage of labour on
PPH, severe PPH and average postpartum blood loss were
analysed by random-effects meta-analysis to avoid
assumptions about similarity of study design or interven-
tions. This systematic review presents Mantel–Haenszel
odds ratios (ORs) for dichotomous (PPH and severe
PPH) outcome, mean differences in blood loss and 95%
conﬁdence intervals (CIs). Heterogeneity across trials is
evaluated using the chi-square test as calculated in Meta-
View. Subgroup analyses are presented for methodologi-
cally adequate studies, and ﬁgures with subgroup
summary statistics are presented to demonstrate effects in
individual studies and their settings. Observational stud-
ies or studies that compare different mechanisms of
providing a single uterotonic are not included in the
meta-analysis. In one study, only the comparison of the
double-blind route was included when multiple routes of
administration were studied to avoid over-counting the
comparison group. Data on methergine were excluded as
methergine was rarely assessed. Analyses were not strati-
ﬁed by dose or route (intravenous, intramuscular
injection, oral, vaginal or rectal) to avoid reducing the
analyses to single studies.
Role of the funding source
The funding source had no role in the study design, data
collection, analysis, interpretation or report composition.
248 search term/criteria eligible articles identified
Excluded (in this order) due to the following reasons:
50 published before 1988 
27 no/unclear/did not report objective measurement of blood loss  
8 no/unclear/did not report outcomes of interest 
8 did not provide uterotonic or conduct expectant management in the
third stage of labour 
1 including caesarean deliveries 
3 multiple articles of same study 
123 publications unavailable (mostly Russian, eastern European and
Chinese). 
29 studies with objective measurement of blood loss
reporting outcomes of interest 
  4 comparing uterotonics rarely assessed and excluded from manuscript, 
1 comparing one of two uterotonics in same study arm with another 
study arm, 1 comparing same uterotonic with and without controlled 
cord traction, 2 observational studies (no comparison groups) 
Meta-analysis data 
21 studies (19 RCTs, 2 QEs) with usable
information for meta-analysis  Number of studies in each meta-analysis 
Mean blood loss H P P e r e v e S H P P
Oxytocin v No Uterotonic  4 6 6
Misoprostol v No Uterotonic  3 6 3
Ergometrine v No Uterotonic  2 2 2
Oxytocin v Misoprostol  3 4 5
Oxytocin v Ergometrine  3 1 3
Misoprostol v Ergometrine  2 2 3
Figure 1. Studies reviewed and included in the meta-analyses.
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Distribution of mean blood loss
The average blood loss ranged from 149 to 548 ml
(Table 2; 16 studies). The highest average blood loss (range
171–548 ml) was among women managed without utero-
tonic prophylaxis (eight studies). The range of average
blood loss was similar in women receiving any prophylactic
uterotonic: 151–499 ml for oxytocin (ten studies, 12 study
arms), 155–443 ml for misoprostol (eight studies, nine
study arms), and 149–476 ml in women receiving ergome-
trine (ﬁve studies, six study arms). The 95% CI of each
study arm was equivalent to 4–28% of the average blood
loss of the study arm. The median average blood loss in
women managed without a uterotonic is about 150–200 ml
higher than for those provided with uterotonics, whereas
the median and range of those managed with uterotonics
are fairly uniform (Figure 2).
Distribution of PPH and severe PPH
The average PPH rate in the nine studies where women
were managed expectantly (without uterotonic prophlyxis)
ranged from 4 to 51% (Table 3). Where uterotonics were
given, PPH ranged from 0 to 32% (17 studies, 19 study
arms) for oxytocin, from 1 to 45% (12 studies) for misopr-
ostol, and from 0 to 37% (seven studies, eight study arms)
for ergometrine. Severe PPH ranged from 0.5 to 17% (12
studies) in women who were managed without prophylac-
tic uterotonics, from 0.4 to 9% (12 studies, 13 study arms)
for women managed with oxytocin, from 0 to 8% (11 stud-
ies) for women managed with misoprostol, and from 0 to
8% (ﬁve studies) for women managed with ergometrine.
A subsample of studies reported both PPH and severe
PPH (Table 3). The ratio of severe PPH to PPH should
theoretically be similar regardless of how the third stage of
labour was managed, unless a uterotonic has the character-
istic of being more effective at preventing blood loss at
lower or higher levels of blood loss. The ratio of severe
PPH to PPH also varied from 10 to 33% for expectant
management, from 6 to 41% for oxytocin, from 0 to 31%
for misoprostol, and from 0 to 30% for ergometrine.
In study sample arms with £200 women the range of
severe PPH to PPH was 0–41%. In the larger study arms
the range of severe PPH to PPH was slightly narrower:
4–33%.
Association of the management of the third stage
of labour with blood loss measured
Oxytocin versus expectant management
In all controlled studies of measured blood loss (Figure S1;
Table 4), oxytocin signiﬁcantly reduced PPH (OR 0.43,
95% CI 0.23–0.81; six studies, n = 6892), and reduced
Table 2. Mean and 95% CI of measured postpartum blood loss by
third-stage prophylactic regimen
Regimen Study
(author, year)
Mean
blood
loss (ml)
95% CI
No
uterotonic
Angola: Strand, 2005
26 445 424–476
Guinea Bissau, rural:
Høj, 2005
42
496 475–517
India, rural: Derman, 2006
24 262 248–276
Ireland: Begley, 1990
49 235 218–251
The Netherlands,
multicentre:
De Groot, 1996
50
520 451–589
The Netherlands:
Poeschmann, 1991
35
548 398–698
Sweden: Nordstrom, 1997
25 527 490–564
Turkey: Ozkaya, 2005
36 171 139–204
Oxytocin Angola: Strand, 2005
26 224 211–238
Egypt: Abdel-Aleem, 2006
48 282 248–315
Egypt: Abdel-Aleem, 2006
48 204 180–228
India: Gupta, 2006
44 151 137–165
India: Zachariah, 2006
29 183 173–193
Japan: Fujimoto, 2006
51 207 167–247
Japan: Fujimoto, 2006
51 288 244–332
Mozambique:
Bugalho, 2001
46
157 142–172
The Netherlands,
multicentre:
De Groot, 1996
50
499 398–600
The Netherlands:
Poeschmann, 1991
35
374 271–477
Sweden: Nordstrom, 1997
26 409 379–439
UK: Mitchell, 1993
41 252 229–275
Misoprostol Gambia, rural:
Walraven, 2005
53
281 267–295
Guinea Bissau, rural:
Høj, 2005
42
443 415–471
India, rural: Derman, 2006
24 214 204–224
India: Gupta, 2006
44 168 153–183
India, rural: Vimala, 2004
31 185 171–199
India: Zachariah, 2006
29 193 183–202
Mozambique:
Bugalho, 2001
46
155 142–168
Turkey: Ozkaya, 2005
36 206 168–245
Turkey: Ozkaya, 2005
36 171 141–201
Ergometrine Gambia, rural:
Walraven, 2005
53
292 278–306
India: Zachariah, 2006
29 188 178–198
Ireland: Begley, 1990
49 149 140–158
Japan: Fujimoto, 2006
51 338 289–387
Japan: Fujimoto, 2006
51 276 243–309
The Netherlands,
multicentre:
De Groot, 1996
50
476 421–531
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four studies, n = 2833) and was associated with substan-
tially but not signiﬁcantly lower rates of severe PPH
(OR 0.61, 95% CI 0.29–1.29; six studies, n = 6892), com-
pared with expectant management (no uterotonic prophy-
laxis). Signiﬁcant heterogeneity (differences between
studies) was observed in these results. Limiting the analyses
to studies qualiﬁed as methodologically adequate eliminates
the heterogeneity, as it reduces the analyses to one study
(n = 1000). In adequate studies, oxytocin signiﬁcantly
reduced PPH (OR 0.45, 95% CI 0.34–0.60), and reduced
the mean blood loss by 118 ml (95% CI from )165 to
)71 ml). The association with severe PPH is marginally
signiﬁcant (OR 0.76, 95% CI 0.52–1.09). Similarly, oxyto-
cin substantially but not signiﬁcantly lowered severe PPH
in the two studies conducted in developing countries, both
of which were quasi-experimental (and thus did not qualify
as methodologically adequate) (OR 0.42, 95% CI 0.04–4.81;
two studies, n = 5203).
26,32
Misoprostol versus expectant management
Compared with no uterotonic prophylaxis, misoprostol was
marginally associated with a substantial reduction in PPH
(OR 0.73, 95% CI 0.50–1.08, three studies, n = 2687) and
severe PPH (OR 0.74, 95% CI 0.52–1.04, six studies,
n = 4328), and was signiﬁcantly associated with a lower
mean blood loss ()38.75 ml, 95% CI from )64.81 to
)12.70 ml, three studies, n = 2833; Figure S2; Table 4).
Signiﬁcant heterogeneity was observed in the analysis of
PPH. Limiting the analyses to studies qualiﬁed as methodo-
logically adequate reduces the heterogeneity to marginally
signiﬁcant (P = 0.06), and conﬁrms the effect of misopros-
tol on reducing PPH compared with expectant manage-
ment (OR 0.63, 95% CI 0.41–0.99, two studies, n = 2281);
both studies were conducted in rural areas of developing
countries. In adequate studies (all in developing countries),
misoprostol also signiﬁcantly reduces severe PPH (OR 0.67,
95% CI 0.51–0.89, ﬁve studies, n = 3922) and mean blood
loss ()39 ml, 95% CI from )65 to )13 ml, three studies,
n = 2373).
24,28,42,43,52
Ergometrine versus expectant management
Compared with no uterotonic, management with ergome-
trine was associated with a signiﬁcant reduction in mean
blood loss ()84 ml, 95% CI from )102 to )66 ml, two
studies, n = 1718; Figure S3; Table 4). Whereas women
receiving ergometrine had substantially lower PPH and
severe PPH in all controlled studies (PPH, OR 0.46, 95%
CI 0.11–1.91; severe PPH, OR 0.32, 95% CI 0.04–2.43, two
studies, n = 1718), the differences were not statistically sig-
niﬁcant. None of the studies comparing ergometrine with
expectant management was considered methodologically
adequate, and none was conducted in developing countries.
Oxytocin versus misoprostol
Compared with misoprostol, oxytocin signiﬁcantly reduced
PPH (all controlled studies and adequate studies, OR 0.65,
95% CI 0.60–0.70, ﬁve studies, n = 20 868; Figure S4;
Table 4) and severe PPH (all controlled studies, OR 0.71,
95% CI 0.56–0.91, four studies, n = 19 789; adequate stud-
ies, OR 0.70, 95% CI 0.60–0.83, two studies, n = 18 941).
These odds ratios and 95% conﬁdence limits of all studies
and the adequate studies subgroup are identical, as the
results are greatly inﬂuenced by the single WHO multicen-
tre study.
45 There was no considerable or signiﬁcant differ-
ence between oxytocin and misoprostol in the two
non-multicentre RCTs considered to be of adequate quality,
which were conducted in much smaller tertiary care centres
in developing countries (PPH, OR 0.83, 95% CI 0.51–1.37;
severe PPH, OR 1.28, 95% CI 0.15–10.95, n = 1081) or in
any of the studies solely conducted in developing countries
(Figure S4). There was no difference in mean blood loss
(all controlled studies, )8 ml, 95% CI from )18 to 2 ml,
three studies, n = 2209; adequate studies, )17 ml, 95% CI
from )37 to 4 ml, one study, n = 200). No statistical heter-
ogeneity was observed in the comparisons. With the excep-
tion of one small study and the Ireland and Switzerland
sites in the multicentre trial, these studies were conducted
in developing country hospitals, none of which were in
rural areas.
Oxytocin or misoprostol versus ergometrine
Oxytocin compared with ergometrine was associated with
substantially lower PPH (oxytocin, OR 0.72, 95% CI
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Figure 2. Median and range of average measured blood loss by
regimen used to manage the third stage of labour.
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Prophylactic regimen Study % PPH % Severe PPH Ratio % Severe PPH to PPH
No uterotonic Angola: Strand, 2005
26 40.41 7.42 18.36
France: Benchimol, 2001
47 27.27 5.91 21.67
Guinea Bissau, rural: Høj, 2005
42 51.36 16.92 32.94
India, rural: Derman, 2006
24 12 1.24 10.33
Ireland: Begley, 1990
49 8.29 1.52 18.34
The Netherlands, multicenter: de Groot, 1996
50 38.46 11.19 29.10
The Netherlands: Poeschmann, 1991
35 41.67 12.5 30.00
South Africa: Bamigboye, 1998
28 NR 6.99
South Africa: Hofmeyr, 1998
23 NR 9.2
South Africa: Hofmeyr, 2001
43 NR 9.7
Sweden: Nordstrom, 1997
25 35.93 8.83 24.58
Vietnam: Tsu, 2006
32 3.84 0.51 13.28
Oxytocin Angola: Strand, 2005
26 8.23 0.98 11.91
Egypt: Abdel-Aleem, 2006
48 4.08 NR
Egypt: Abdel-Aleem, 2006
48 7.84 NR 41.38
France: Benchimol, 2001
47 14.79 6.12 41.38
Hong Kong: Yuen, 1995
30 12.12 2.02 16.67
India: Gupta, 2006
44 0N R
India: Zachariah, 2006
29 2.11 0.65 30.81
Israel: Soriano, 1996
33 9.73 NR
Japan: Fujimoto, 2006
51 11.58 NR
Japan: Fujimoto, 2006
51 7.32 NR
Multicentre Gulmezoglu, 2001
40 13.53 2.85 21.06
The Netherlands, multicentre: de Groot, 1996
50 32.05 8.97 27.99
The Netherlands: Poeschmann, 1991
35 25.0 7.14 28.56
Sweden: Nordstrom, 1997
25 20.27 6.24 30.78
UAE: Khan, 1997
41 10.96 3.17 28.92
UAE: Khan, 1997
41 5.8 0.73 12.59
UK: Mitchell, 1993
41 7.39 0.43 5.82
Vietnam: Tsu, 2006
32 2.67 0.73 27.34
Zimbabwe: Kundodyiwa, 2001
40 13.28 1.95 14.68
Misoprostol Egypt: Prata, 2006
34 1.61 0.08 4.97
France: Benchimol, 2001
47 27.95 8.6 30.77
Gambia, rural: Walraven, 2005
53 10.97 0.32 2.92
Guinea Bissau, rural: Høj, 2005
42 45.45 11.21 24.66
Hong Kong: Lam, 2004
39 13.33 NR
India, rural: Derman, 2006
24 6.4 0.25 3.91
India: Gupta, 2006
44 1
India: Verma, 2006
31 1N R
India, rural: Vimala, 2004
52 3.33 0 0
India: Zachariah, 2006
29 2.6 0.14 5.38
South Africa: Bamigboye, 1998
28 4.81
South Africa: Hofmeyr, 1998
23 NR 6.0
South Africa: Hofmeyr, 2001
43 NR 9.0
Zimbabwe: Kundodyiwa, 2001
40 15.23 3.7 24.29
Multicentre Gulmezoglu, 2001
40 19.46 3.97 20.40
Ergometrine Gambia, rural: Walraven, 2005
53 12.02 0.67 5.57
India: Verma, 2006
31 0N R
India, rural: Vimala, 2004
52 00 0
India: Zachariah, 2006
29 2.96 0.89 30.07
Ireland: Begley, 1990
49 1.99 0.14 7.04
Japan: Fujimoto, 2006
51 7.59 NR
Japan: Fujimoto, 2006
51 18.57 NR
The Netherlands, multicentre: de Groot, 1996
50 36.99 8.22 22.22
NR, not reported.
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cin, OR 0.73, 95% CI 0.20–2.59, one study, n = 1293),
although neither difference was statistically signiﬁcant (Fig-
ure S5; Table 4). There was little difference in mean blood
loss in women receiving oxytocin compared with ergome-
trine ()37 ml, 95% CI from )106 to 33 ml, three studies,
n = 1619). In the single study in India (which was not of
adequate quality), the results comparing oxytocin with erg-
ometrine were almost identical to all studies comparing
oxytocin with ergometrine (PPH, OR 0.71, 95% CI 0.35–
1.43; severe PPH, OR 0.73, 95% CI 0.20–2.59; mean blood
loss )5 ml, 95% CI from )20 to 10 ml, n = 1293).
Women who received misoprostol had similar PPH rates
and mean blood loss to those receiving ergometrine (PPH,
OR 0.91, 95% CI 0.67–1.23, three studies, n = 2834; mean
blood loss )2 ml 95% CI from )17 to 13 ml, two studies,
n = 2634; Figure S6; Table 4). However, women receiving
misoprostol had substantially and marginally signiﬁcantly
lower rates of severe PPH than those receiving ergometrine
(OR 0.30, 95% CI 0.08–1.15, P = 0.08, two studies,
n = 2634). Only one study on rural Gambian home deliv-
eries, comparing misoprostol with ergometrine, was consid-
ered to be adequate: there was no substantial difference in
PPH or mean blood loss, but misoprostol was associated
with a large yet not statistically signiﬁcantly lower rate of
severe PPH (OR 0.47, 95% CI 0.09–2.60, n = 1228).
53 All
studies comparing misoprostol with ergometrine were con-
ducted in developing countries.
Discussion
The WHO recommends oxytocin as the uterotonic of
choice for PPH prevention, and that oxytocin or misopros-
tol be offered by a health worker trained in its use in the
absence of oxytocin and other components of AMTSL, e.g.
provision of a uterotonic, uterine massage and controlled
cord traction.
8 These recommendations are currently based
upon a body of studies that do not distinguish between
visual and measured blood loss, and are inﬂuenced by the
sample for which blood loss was visually assessed. Similarly,
Table 4. Effect of prophylactic regimen of third stage of labour on PPH, severe PPH and mean blood loss (in ml)
Outcome Studies n Effect estimate
OR/mean difference
[95% CI]
P Studies n Effect estimate
OR/mean difference
[95% CI]
P
All studies Adequate quality RCT subgroup
Oxytocin versus no uterotonic
PPH 6 6892 0.43 [0.23, 0.81]* <0.001 1 1000 0.45 [0.34, 0.60] <0.001
Severe PPH 6 6892 0.61 [0.29, 1.29]* 0.20 1 1000 0.76 [0.52, 1.09] 0.12
Mean blood loss 4 2833 )140.35 [)228.54, )52.16]* 0.001 1 1000 )118.00 [)165.23, )70.77] <0.001
Misoprostol versus no uterotonic
PPH 3 2687 0.73 [0.50, 1.08]* 0.12 2 2281 0.63 [0.41, 0.99]** 0.04
Severe PPH 6 4328 0.74 [0.52, 1.04] 0.09 5 3922 0.67 [0.51, 0.89] 0.005
Mean blood loss 3 2373 )38.75 [)64.81, )12.70] 0.004 3 2373 )38.75 [)64.81, )12.70] 0.004
Ergometrine versus no uterotonic
PPH 2 1718 0.46 [0.11, 1.91]* 0.29
Severe PPH 2 1718 0.32 [0.04, 2.43]** 0.27
Mean blood loss 2 1718 )84.07 [)102.47, )65.67] <0.001
Oxytocin versus misoprostol
PPH 5 20868 0.65 [0.60, 0.70] <0.001 3 19139 0.65 [0.60, 0.70] <0.001
Severe PPH 4 19789 0.71 [0.56, 0.91] 0.005 2 18941 0.70 [0.60, 0.83] <0.001
Mean blood loss 3 2209 )8.36 [)18.32, 1.61] 0.10 1 200 )16.70 [)36.96, 3.56] 0.11
Oxytocin versus ergometrine
PPH 3 1619 0.72 [0.34, 1.56] 0.41
Severe PPH 1 1293 0.73 [0.20, 2.59] 0.63
Mean blood loss 3 1619 )36.97 [)106.47, 32.53]* 0.30
Misoprostol versus ergometrine
PPH 3 2834 0.91 [0.67, 1.23] 0.53 1 1228 0.90 [0.63, 1.28] 0.56
Severe PPH 2 2634 0.30 [0.08, 1.15] 0.08 1 1228 0.47 [0.09, 2.60] 0.39
Mean blood loss 2 2634 )1.64 [)16.50, 13.22] 0.83 1 1228 )11.00 [)30.75, 8.75] 0.28
*Signiﬁcant heterogeneity.
**Borderline signiﬁcant heterogeneity (P = 0.06–0.10).
Sloan et al.
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not separate studies for other factors that inﬂuence bleed-
ing. The American College of Obstetricians and Gynecolo-
gists has suggested functional deﬁnitions of severe blood
loss, including a 10% decline from ante- to post-partum
haematocrit, or the need for red blood cell transfusion;
55
however, too few studies measuring blood loss exist to sup-
port such functional deﬁnitions.
By reviewing only articles of measured postpartum blood
loss, this article provides comparisons unbiased by the pro-
portion of studies using visual compared with measured
blood loss. Most of the presented analyses show similar
effects to those published in meta-analyses that pool visu-
ally estimated and measured blood loss; however, our anal-
yses clarify some important discrepancies.
17 Comparing
oxytocin with no uterotonic, our analyses of all studies
show a slightly stronger and still signiﬁcant effect for PPH
and mean blood loss (PPH, OR 0.43, 95% CI 0.23–0.81
versus Cochrane OR 0.50, 95% CI 0.43–0.59; mean blood
loss of )140 ml, 95% CI from )229 to )52 ml versus
Cochrane blood loss of )102 ml, 95% CI from )135 to
)69 ml), with the same effect on severe PPH (OR 0.61,
95% CI 0.29)1.29 versus Cochrane 95% CI 0.44–0.87). As
a smaller subgroup, our analyses of severe PPH do not
reach statistical signiﬁcance.
17 Our analyses of studies of
adequate quality compared with the Cochrane subgroup of
RCTs demonstrate a signiﬁcant and much stronger reduc-
tion of PPH with oxytocin compared with no uterotonic
(OR 0.45, 95% CI 0.34–0.60 versus Cochrane OR 0.61,
95% CI 0.51–0.72), and a reduction in mean blood loss
()118 ml, 95% CI from )165 to )71 ml versus Cochrane
mean blood loss of )109 ml, 95% CI from )152 to
)66 ml), whereas the effect on severe PPH was similar, and
was still marginally signiﬁcant (OR 0.76, 95% CI 0.52)1.09
versus Cochrane OR 0.72, 95% CI 0.49–1.05).
The Cochrane comparisons of misoprostol with no or
other uterotonics are less methodologically similar to our
analyses.
8 The Cochrane review of prostaglandins for PPH
prevention does not provide estimates summarising the
overall effect comparing misoprostol with no uterotonic;
however, the estimate we calculate from the data they pres-
ent for this comparison, excluding the Gambian study
53 (as
the comparison group received oral ergometrine) and the
Turkish study
36 (which compared a combination of oxyto-
cin and misoprostol with no uterotonic), was Cochrane
OR 0.75 (95% CI 0.49–1.14) for severe PPH, very similar
to our results from all studies (OR 0.74, 95% CI 0.52–
1.04), although our adequate-quality studies showed a
stronger and highly signiﬁcant effect (OR 0.67, 95% CI
0.51–0.89). The Cochrane review found that compared with
sublingual misoprostol, any injectable uterotonic had a
similar yet marginally signiﬁcant effect on PPH (Cochrane
OR 0.93, 95% CI 0.79–1.11), and was inferior to sublingual
misoprostol for severe PPH (Cochrane OR 1.85, 95% CI
0.79–4.35). In contrast, the Cochrane review found any
injectable uterotonic to be superior to oral misoprostol for
severe PPH (Cochrane OR 0.76, 95% CI 0.66–0.86).
8
The effects of uterotonics on severe PPH are particularly
important, as maternal death as a result of PPH usually
occurs when blood loss is >1000 ml.
19 Distinct from exist-
ing reviews, we found that prophylactic oxytocin signiﬁ-
cantly reduces PPH, but is only marginally associated with
lower severe PPH compared with expectant management.
This might be attributable to insufﬁcient statistical power,
as severe PPH is a relatively rare condition. In addition, a
small portion of PPH and severe PPH would not be
responsive to uterotonics (for example, if caused by
trauma), thereby minimising the incidence of potentially
responsive severe bleeding. However, compared with no
uterotonic, misoprostol signiﬁcantly lowered severe PPH in
adequate-quality studies with a much smaller total sample
size than that of all studies evaluating the effects of oxyto-
cin on severe PPH. The data from adequate-quality studies
or developing country data are too scant to draw conclu-
sions about the effects of oxytocin compared with no
uterotonic, or misoprostol, in these contexts.
Prophylactic misoprostol signiﬁcantly reduces PPH and
severe PPH, compared with expectant management, only
when analyses are limited to adequate-quality studies, or in
studies solely conducted in developing countries. In the
WHO multicentre study comparing oxytocin with misopr-
ostol in hospital settings, oxytocin reduces PPH and severe
PPH signiﬁcantly more than misoprostol, but does not dif-
ferentially affect maternal death.
45 Four studies of misopr-
ostol have been conducted in rural, developing country
settings: two compared with ergometrine and two with no
uterotonic. There is only one quasi-experimental study of
oxytocin in a rural developing country setting. No studies
compare oxytocin with misoprostol in home birth or pri-
mary care centre settings, or in rural areas of developing
countries, where misoprostol being simpler, and therefore
more feasible to administer and study, may be relatively
more effective because of greater coverage.
Distinct from other reviews, this review of measured
blood loss, complementing meta-analyses with broader epi-
demiologic data, and providing sufﬁcient stratiﬁcation of
information, demonstrates that women experience a large
range of postpartum blood loss, even when bleeding was
carefully measured. The median of reported average blood
loss in women receiving any prophylactic uterotonics was
similar, and was approximately 40% lower than that of
women not receiving prophylactic uterotonics. However, the
range of average blood loss, PPH and severe PPH was large,
and fairly consistent, across women receiving and not receiv-
ing prophylactic uterotonics. The difference between the
lowest and highest mean blood loss, incidence of PPH and
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regimen for managing the third stage of labour is greater
than the discrepancy in these ranges across the regimens.
Variation in blood loss was only slightly larger in study arms
with £200 women compared with larger study arms.
Women’s characteristics, obstetric practices and other
factors associated with setting could account for some of
the blood loss variation, and for the differences in the rela-
tive effectiveness of uterotonics on blood loss and haemor-
rhage.
10 Eligible studies generally excluded high-risk or
complicated pregnancies. Labour augmentation and/or
induction were permitted in about half of the reviewed
studies with 2–47% (median 27%) of women having aug-
mentation or induction. In women otherwise managed
without uterotonic prophylaxis, study arms that permitted
augmentation or induction had lower levels of blood loss
than those without. Measuring blood loss is more difﬁcult
than visual estimation, and thus has been implemented less
frequently. Although blood loss measurement could in the-
ory inﬂuence observed blood loss, few studies used the
drape, and both the bedpan/linens and drape methods are
direct measurements that are found to be quite accurate
and similar.
56,57 Exclusion of studies where the incidence of
PPH was extremely high, or limiting analyses to studies
measuring blood loss for 1 hour, only slightly modiﬁed the
incidence of severe PPH for all regimens.
Conclusions
A better understanding of postpartum blood loss could
improve our strategies to prevent and manage PPH, partic-
ularly in the rural developing country settings where most
maternal deaths occur, yet where few adequate-quality
studies have taken place. Our results of measured blood
loss indicate that although oxytocin is superior to misopr-
ostol in hospitals, misoprostol substantially lowers PPH
and severe PPH in developing countries. The relative merits
of oxytocin and misoprostol continue to require sound
assessment in rural areas of developing countries, where
most PPH deaths occur.
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